Department of Medicine, McMaster University, Hamilton, ON, Canada.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Crit Care Med. 2018 Sep;46(9):1411-1420. doi: 10.1097/CCM.0000000000003262.
This systematic review and meta-analysis addresses the efficacy and safety of corticosteroids in critically ill patients with sepsis.
We updated a comprehensive search of MEDLINE, EMBASE, CENTRAL, and LILACS, and unpublished sources for randomized controlled trials that compared any corticosteroid to placebo or no corticosteroid in critically ill children and adults with sepsis.
Reviewers conducted duplicate screening of citations, data abstraction, and, using a modified Cochrane risk of bias tool, individual study risk of bias assessment.
A parallel guideline committee provided input on the design and interpretation of the systematic review, including the selection of outcomes important to patients. We assessed overall certainty in evidence using Grading of Recommendations Assessment, Development and Evaluation methodology and performed all analyses using random-effect models. For subgroup analyses, we performed metaregression and considered p value less than 0.05 as significant.
Forty-two randomized controlled trials including 10,194 patients proved eligible. Based on low certainty, corticosteroids may achieve a small reduction or no reduction in the relative risk of dying in the short-term (28-31 d) (relative risk, 0.93; 95% CI, 0.84-1.03; 1.8% absolute risk reduction; 95% CI, 4.1% reduction to 0.8% increase), and possibly achieve a small effect on long-term mortality (60 d to 1 yr) based on moderate certainty (relative risk, 0.94; 95% CI, 0.89-1.00; 2.2% absolute risk reduction; 95% CI, 4.1% reduction to no effect). Corticosteroids probably result in small reductions in length of stay in ICU (mean difference, -0.73 d; 95% CI, -1.78 to 0.31) and hospital (mean difference, -0.73 d; 95% CI, -2.06 to 0.60) (moderate certainty). Corticosteroids result in higher rates of shock reversal at day 7 (relative risk, 1.26; 95% CI, 1.12-1.42) and lower Sequential Organ Failure Assessment scores at day 7 (mean difference, -1.39; 95% CI, -1.88 to -0.89) (high certainty). Corticosteroids likely increase the risk of hypernatremia (relative risk, 1.64; 95% CI, 1.32-2.03) and hyperglycemia (relative risk, 1.16; 95% CI, 1.08-1.24) (moderate certainty), may increase the risk of neuromuscular weakness (relative risk, 1.21; 95% CI, 1.01-1.52) (low certainty), and appear to have no other adverse effects (low or very low certainty). Subgroup analysis did not demonstrate a credible subgroup effect on any of the outcomes of interest (p > 0.05 for all).
In critically ill patients with sepsis, corticosteroids possibly result in a small reduction in mortality while also possibly increasing the risk of neuromuscular weakness.
本系统评价和荟萃分析旨在探讨皮质类固醇在脓毒症危重症患者中的疗效和安全性。
我们更新了对 MEDLINE、EMBASE、CENTRAL 和 LILACS 的全面检索,并对比较任何皮质类固醇与安慰剂或无皮质类固醇治疗脓毒症危重症儿童和成人的随机对照试验进行了未发表来源的检索。
审查员对引用进行了重复筛选、数据提取,并使用改良的 Cochrane 偏倚风险工具对个别研究的偏倚风险进行了评估。
一个平行的指南委员会就系统评价的设计和解释提供了投入,包括选择对患者重要的结局。我们使用 Grading of Recommendations Assessment, Development and Evaluation 方法评估证据的总体确定性,并使用随机效应模型进行所有分析。对于亚组分析,我们进行了荟萃回归,并认为 p 值小于 0.05 为有统计学意义。
42 项随机对照试验,共纳入 10194 例患者,证明符合入选标准。基于低确定性,皮质类固醇可能在短期内(28-31 天)降低或不降低死亡率的相对风险(相对风险,0.93;95%CI,0.84-1.03;1.8%绝对风险降低;95%CI,4.1%降低至 0.8%增加),并可能基于中度确定性对长期死亡率(60 天至 1 年)产生较小影响(相对风险,0.94;95%CI,0.89-1.00;2.2%绝对风险降低;95%CI,4.1%降低至无影响)。皮质类固醇可能会降低 ICU (平均差,-0.73 天;95%CI,-1.78 至 0.31)和医院(平均差,-0.73 天;95%CI,-2.06 至 0.60)的住院时间(中度确定性)。皮质类固醇可使第 7 天休克逆转率更高(相对风险,1.26;95%CI,1.12-1.42),第 7 天序贯器官衰竭评估评分更低(平均差,-1.39;95%CI,-1.88 至-0.89)(高确定性)。皮质类固醇可能增加高钠血症的风险(相对风险,1.64;95%CI,1.32-2.03)和高血糖的风险(相对风险,1.16;95%CI,1.08-1.24)(中度确定性),可能增加神经肌肉无力的风险(相对风险,1.21;95%CI,1.01-1.52)(低确定性),并且似乎没有其他不良影响(低或极低确定性)。亚组分析未显示出任何有意义的亚组效应(所有 p 值均大于 0.05)。
在脓毒症危重症患者中,皮质类固醇可能降低死亡率,但也可能增加神经肌肉无力的风险。